Tempo Therapeutics

Tempo Therapeutics is a private, preclinical-stage biotech company pioneering a novel tissue engineering platform called MAP (Microporous Annealed Particle). This technology creates synthetic, immune-modulating scaffolds that promote regeneration and avoid scarring, with initial applications in biosurgery for dermal and abdominal wall reconstructions. The company is led by a scientifically robust team, including founders from academia, and is exploring broader applications in drug delivery and cell engraftment. Tempo is pre-revenue and actively seeking strategic partnerships to advance its pipeline and expand into new therapeutic areas.

MAP (Microporous Annealed Particle) technology: a synthetic, immune-modulating scaffold platform that polarizes host immunity to a pro-regenerative state to drive functional tissue growth and avoid scarring. It is material-agnostic and can be combined with drug/cell delivery systems.

Tempo competes in the crowded regenerative medicine and advanced wound care space, facing large players like Integra LifeSciences, Baxter, and Medtronic, as well as biotech firms developing scaffold and cell-based therapies. Its key differentiation is the specific immunomodulatory property of its MAP scaffold designed to actively promote a regenerative immune response.